About: Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug, as well as with JCR Pharmaceuticals Co. Ltd for the development of Aß oligomer-targeted enhanced brain delivery therapy for the treatment of Alzheimer's disease. The company was incorporated in 1996 and is headquartered in Newton, Massachusetts.
Sector: Healthcare
Industry: Biotechnology
Latest price: $2.02 (-5.61%)
ABOS NASDAQ Acumen Pharmaceuticals Inc
Acumen Pharmaceuticals Inc share price
ABOS price activity
Last Price
$2.020
Change (24hr)
-0.12 USD (-5.61%)
Volume
290.60K
Volume (4w avg)
-
Open
$2.14
Day Range
$2.00 - $2.14
Previous Close
$2.14
Last Trade
12 Oct, 8:00 pm GMT+0
Delayed
12 Oct, 8:00 pm GMT+0
ABOS price performance
Delayed
12 Oct, 8:00 pm GMT+0
ABOS Market Signals